|Day Low/High||48.15 / 49.06|
|52 Wk Low/High||44.30 / 68.22|
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
Stocks rose Monday amid another rush of earnings reports this week including Alphabet results due after the bell.
Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.
Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.
Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.
Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.
News follows Bristol-Myers Squibb's planned $74 billion buy of Celgene. TheStreet.com could not verify the report.
Jim Cramer makes sense of this market action and has your game plan for next week.
Jim Cramer takes a closer look at Bank of America, Kemet, Boston Beer, Diageo, Pilgrim's Pride, Tyson Foods, Moderna and more.
Management commentary from CAT is key on Monday.
Bristol-Myers Squibb posts stronger-than-expected fourth-quarter earnings but pulls an application to the U.S. Food and Drug Administration for a blockbuster cancer drug combination in order to collect more data.
Stocks ended mixed as global investors remain in defensive positions amid ongoing concerns over the strength of the world economy and the fate of U.S.-China trade talks.
Replacing fear with pragmatism, that is our goal.
U.S. equity futures edged higher Thursday, helped in part by stronger-than-expected semiconductor earnings, even as global investors remained defensive positions amid ongoing concerns over the strength of the world economy, the fate of U.S.-China trade talks and the potential for a change in tack from key central banks.
U.S. stock futures rise modestly as investors retreat largely to defensive positions amid ongoing concerns over the strength of the world economy; Ford swings to a loss because of overseas weakness; Intel, Starbucks and Western Digital report earnings Thursday; Microsoft's Bing search engine is blocked in China.
These themes are working despite the turmoil in Washington and slowing global growth.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2018 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that its fourth quarter 2018 earnings call has been rescheduled for two hours earlier than previously announced.
Global stocks stalled Thursday, with investors largely retreating to defensive positions amid ongoing concerns over the strength of the world economy, the fate of U.S.-China trade talks and the potential for a change in tack from key central banks.
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
Big pharma is shaping up to be a consolidating category in 2019.
Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.
Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.
Left's firm Citron Research gives the $100+ stock a $35 price target.
The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.